Checkpoint blockade after kidney transplantation

Lesouhaitier, Mathieu;Dudreuilh, Caroline;Tamain, Mathilde;Kanaan, Nada;Houot, Roch;et.al.
(2018) European Journal of Cancer — Vol. 96, p. 111-114 (2018)

Files

2018_Lesouhaitier_Eur_J_Cancer.pdf
  • Restricted Access
  • Adobe PDF
  • 313.18 KB
Request a copy

Details

Authors
  • Lesouhaitier, Mathieu
    Author
  • Dudreuilh, Caroline
    Author
  • Tamain, Mathilde
    Author
  • Kanaan, NadaUCLouvain
    Author
  • Houot, Roch
    Author
Show more
Abstract
(en) Dear Editor, Immune checkpoint inhibitors (CPIs) have opened a new era in the treatment of cancer, and their indications are increasing rapidly. To date, these CPIs include anti-CTLA4 (ipilimumab), anti-Programmed Death 1 (PD1) (nivolumab, pembrolizumab) and anti-Programmed Death-Ligand 1 (PD-L1) (atezolizumab, avelumab, durvalumab) antibodies (Abs). Solid organ transplant recipients have a higher risk of neoplastic complications because of immunosuppressive treatments and oncogenic viral infections [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lesouhaitier, M., Dudreuilh, C., Tamain, M., Kanaan, N., Bailly, E., Legoupil, D., Deltombe, C., Perrin, P., Manson, G., Vigneau, C., & Houot, R. (2018). Checkpoint blockade after kidney transplantation. European Journal of Cancer, 96, 111-114. https://doi.org/10.1016/j.ejca.2018.03.019 (Original work published 2018)